期刊文献+

抗人喉癌单克隆抗体轻链可变区基因的克隆

Cloning of the light chain variable region gene of monoclonal antibody against human laryngeal carcinoma
下载PDF
导出
摘要 目的分离抗人喉癌单克隆抗体LC9-G5轻链可变区(light chain variable region,VL)基因,并测定分析其核苷酸序列。方法使用PCR方法体外扩增抗人喉癌单克隆抗体LC9-G5 VL基因,将其克隆入PMD18-T载体,重组子测序,将其序列使用数据库NCBI和Kabat进行分析。结果这段序列与小鼠卵巢癌抗体VL基因的同源性为99%,基因全长336 bp,属于小鼠免疫球蛋白轻链第Ⅱ亚类,该VL基因序列已被Gene Bank收录,收录号为U60463。结论该基因为抗人喉癌单克隆抗体LC9-G5轻链可变区基因。 OBJECTIVE To amplify and sequence the light chain variable region(VL) gene of monoclonal antibody (McAb) against human laryngeal carcinoma. METHODS The VL gene of mouse McAb against human laryngeal carcinoma was amplified by polymerase chain reaction(PCR). The PCR product was then cloned into PMD18-T vector. The recombinants were sequenced. The VL gene was compared with published mouse VL gene by NCBI and Kabat. RESULTS It was proved that a full-length VL gene was 336 bp, the VL gene was a member of mouse immunoglobulin (Ig)light chain subgroup Ⅱ. The VL gene sequence was registered by Gene Bank (accession No. U60463). CONCLUSION The obtained VL gene is potentially the functional gene of the McAb against human laryngeal carcinoma.
出处 《中国耳鼻咽喉头颈外科》 北大核心 2006年第9期633-635,共3页 Chinese Archives of Otolaryngology-Head and Neck Surgery
基金 吉林省科技厅重点项目(20040411-2) 吉林大学创新基金项目(419070200064) 吉林大学研究生创新基金项目(医学704054)
关键词 喉肿瘤 抗体 单克隆 免疫球蛋白类 轻链 克隆 分子 序列分析 Laryngeal Neoplasm Antibodies Monoclonal Imrnunoglobulins, Light-China Cloning, Molecular Sequence Analysis
  • 相关文献

参考文献10

  • 1[1]Skrepnik N,Zieske AW,Robert E,et al.Aggressive administration of recombinant oncotoxin AR209 (anti-ErbB-2) in athymic nude mice implanted with orthotopic human non-small cell lung tumours.EurJ Cancer,1998,34:1628-1633.
  • 2[2]Deshane J,Cabrera G,Grim JE,et al.Targeted eradic ation of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.Gynecol Oncol,1995,59:8-14.
  • 3[3]Fang M,Zhao R,Yang Z,et al.Characterization of an anti-human ovarian carcinoma×anti-human CD3 bispecific single-chain antibody with an albumin-original interlinker.Gynecol Oncol,2004,92:135-146.
  • 4[4]Brekke OH,Sandliel.Therapeutic antibodies for human diseases at the dawn of the twenty-first century.Nat Rev Drug Discov,2003,2:52-62.
  • 5管国芳,许亚辉,孙立群,金春顺,杨桂琴,郭丽娟,吕亚忠.抗人喉癌单克隆抗体的制备及其特性研究[J].中华耳鼻咽喉科杂志,1995,30(1):50-52. 被引量:3
  • 6[7]Kontermann R,Dubel S.Antibody engineering.New York:Springer-Verlag,2001:19-56.
  • 7[8]Kabat EA,Wu TT,Perry H,et al.Sequences of proteins of immunological interest.5th ed.Bethesda:NIH Publication,1991:151-257.
  • 8王勇,刘喜富,顾征,萧飒,陈艾,林晴,黄华梁,王登顺,李新元.抗人肺腺癌单克隆抗体重、轻链可变区基因的分离克隆和序列测定[J].Acta Genetica Sinica,1996,23(2):91-95. 被引量:7
  • 9[10]Carroll WL,Mendel E,Levy S.Hybridoma fusion cell lines contain an aberrant kappa transcript.Mol Immunol,1988,25:991-995.
  • 10[11]Kutemeier G,Harloff C,Mocikat R.Rapid isolation of immuno globulin variable genes from cell lysates of rat hybridomas by polymerase chain reaction.Hybridoma,1992,11:23-32.

二级参考文献3

  • 1田道法,国外医学耳鼻咽喉科学分册,1990年,14卷,5页
  • 2陶义训,临床免疫学检验.上,1983年
  • 3吴文书,单克隆抗体通讯,1993年,9卷,3期,55页

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部